Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.
Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients.
Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: A 7 Tesla MRI study.
[Disease modifying drugs in multiple sclerosis and pregnancy.]
The Efficacy of Primidone in Reducing Severe Cerebellar Tremors in Patients With Multiple Sclerosis.
Lack of replication of interaction between EBNA1 IgG and smoking in risk for multiple sclerosis.
Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients.
Hypomorphic MGAT5 polymorphisms promote multiple sclerosis cooperatively with MGAT1 and interleukin-2 and 7 receptor variants.
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.
Very Frequent Fallers and Future Fall Injury: Continuous Risk Among Community-Dwelling Home Care Recipients.
Exercise therapy for fatigue in multiple sclerosis.
Adaptive Immunity in Neurodegenerative and Neuropsychological Disorders.
Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration.
Gait and jogging parameters in people with minimally impaired multiple sclerosis.
Transplantation of autologous adipose stem cells lacks therapeutic efficacy in the experimental autoimmune encephalomyelitis model.
Visual Evoked Potential and Magnetic Resonance Imaging are More Effective Markers of Multiple Sclerosis Progression than Laser Polarimetry with Variable Corneal Compensation.
Multiple sclerosis: Hematopoietic stem cell transplantation: hope and hype.
Political notebook.
Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.
A unified cell biological perspective on axon-myelin injury.
Validity and test-retest reliability of a measure of hand sensibility and manual dexterity in people with multiple sclerosis: the ReSense test.
Flare up reaction during provocation test to glatiramer acetate in a patient with allergy to interferon beta1a.
Activities of the European multiple sclerosis platform.
An overview of the molecular mechanisms and novel roles of Nrf2 in neurodegenerative disorders.
Interaction between passive smoking and two HLA genes with regard to multiple sclerosis risk.
Pages
« first
‹ previous
…
403
404
405
406
407
408
409
410
411
…
next ›
last »